key: cord-0308073-hq28kxe2
authors: Lacy, J.; Mensah, A. A.; Simmons, R.; Andrews, N.; Siddiqui, M. R.; Bukasa, A.; O'Boyle, S.; Campbell, H.; Brown, K. E.
title: Protective effect of a first SARS-CoV-2 infection from reinfection: a matched retrospective cohort study using PCR testing data in England
date: 2022-01-10
journal: nan
DOI: 10.1101/2022.01.10.22268896
sha: af4eeed479c7ed77f53599ea486c0aaf257d0f45
doc_id: 308073
cord_uid: hq28kxe2

The duration of immunity after first SARS-CoV-2 infection and the extent to which prior immunity prevents reinfection is uncertain and remains an important question within the context of new variants. Using a retrospective population-based matched observational study approach, we identified cases with a first PCR positive test between 01 March 2020 and 30 September 2020 and cases were matched by age, sex, upper tier local authority of residence and testing route to individuals testing negative in the same week (controls) by PCR. After a 90-day pre-follow up period for cases and controls, any subsequent positive tests up to 31 December 2020 and deaths within 28 days of testing positive were identified, this encompassed an essentially vaccine-free period. There were 517,870 individuals in the matched cohort with 2,815 reinfection cases and 12,098 first infections. The protective effect of a prior SARS-CoV-2 PCR-positive episode was 78% (OR 0.22, 0.21-0.23). Protection rose to 82% (OR 0.18, 0.17-0.19) after a sensitivity analysis excluded 934 individuals with a first test between March and May and a subsequent positive test between June and September 2020. Amongst individuals testing positive by PCR during follow-up, reinfection cases had 77% lower odds of symptoms at the second episode (adjusted OR 0.23, 0.20-0.26) and 45% lower odds of dying in the 28 days after reinfection (adjusted OR 0.55, 0.42-0.71). Prior SARS-CoV-2 infection offered protection against reinfection in this population. There was some evidence that reinfections increased with the Alpha variant compared to the wild-type SARS-CoV-2 variant highlighting the importance of continued monitoring as new variants emerge.

As of 10 December 2021, 267.9 million COVID-19 cases and 5.3 million associated deaths have been reported globally to the World Health Organisation(1). The first case of COVID-19 disease in the UK was confirmed in January 2020 and by the end of that same year, 52 million PCR tests had been performed with 2.65 million individuals testing positive at least once and 76,406 deaths reported within 28 days of a positive result. Reinfection is associated with seasonal human coronaviruses such as the common cold and there is a recognised need to understand the risk of reinfection in individuals that have recovered from COVID-; a population that will continue to increase.

The duration of immunity after first SARS-CoV-2 infection and the extent to which prior immunity provides protection against disease or transmission remains uncertain. Potential cases of reinfection have been reported internationally (2) (3) (4) (5) (6) . In An analysis of a large, multi-centre, prospective cohort study of hospital healthcare workers in the UK, found that a prior history of SARS-CoV-2 infection was associated with an 84% (95% CI: 81%-87%) lower risk of infection during 7 months of follow up (8) . Similarly, a population-based study in Denmark found prior infection conferred 80% protection against reinfection in those aged 65 years and younger but only 47% protection against reinfection in those aged 65 years or older (9) . A study of 43,000 individuals in Qatar estimated 95.2% (95% CI: 94.1-96.0%) protection against reinfection (10) . A retrospective cohort study of patients in a health system in Ohio and Florida found that the protection offered from prior infection to reinfection was 81.8% (95% CI: 76.6-85.8) at ≥90 days after initial testing (11) . The protection against symptomatic infection was 84.5% (95% CI: 77.9-89.1). A French study of SARS-CoV-2 screening tests found 42.6% of patients presented a similar clinical status upon reinfection (after ≥90 days), 29.5% had a milder form of the disease and 27.8% worsened from asymptomatic to mild or severe disease(12).

The emergence of the Alpha(13), Beta (14) , Gamma (15) , Delta(16) and most recently Omicron (17) SARS-CoV-2 variants was a cause for concern, not only for the apparent increased transmissibility of subsequent variants(13, 18) , associated with mutations in the spike protein (19, 20) but also for the increased risk of hospitalisation (21) and the potential to escape the immune response (22) (23) (24) (25) (26) (27) . It is important to understand if both natural and vaccine-acquired immunity provides protection from SARS-CoV-2 variants.

Using national testing datasets in England we identified people who tested PCR positive for SARS-CoV-2 for the first time between 01 March 2020 and 30

September 2020, as cases. These individuals were matched one-to-one to controls with a negative test result in the same week of test and tested via the same testing route with the same demographic characteristics of age (in years), sex and upper tier local authority of residence. We then looked at the risk in both case and control groups of reporting a positive PCR test within a predetermined follow up period starting 90 days after the last COVID-19 PCR positive test of the cases up until 31 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.10.22268896 doi: medRxiv preprint December 2020. This period therefore predated COVID-19 vaccine effects as vaccination began on 8 December 2020 in highest priority groups and anti-spike IgG levels mature over the 2-4 weeks after the first dose (28) .

The main analysis was a retrospective population-based matched observational study. COVID-19 is a notifiable disease and all laboratories in England are legally obliged to report all SARS-CoV-2 positive test results to Public Health England (PHE) and its successor, the UK Health Security Agency (UKHSA) through the Second Generation Surveillance System (SGSS)(29). The Unified Dataset (USD) consolidates data on positive tests from SGSS with national negative test data on an individual level. All SARS-CoV-2 testing undertaken by NHS or PHE laboratories for hospitalised patients or routine checks for healthcare workers are reported through pillar 1. Testing within the wider community for people reporting symptoms and requesting a test, regular testing of care home residents and their staff are reported through pillar 2.

Due to the limited number of paediatric reinfection cases identified in 2020, individuals in England aged 10 years or older were selected based on a first SARS-CoV-2 positive PCR test result between 01 March 2020 and 30 September 2020.

This ensured that those selected with a positive test, and those matched with an initial negative PCR result, had at least 90 days to become a reinfection or first infection respectively before the end of the study period on 31 December 2020 and enabled review of reinfection risk prior to widespread introduction of vaccination in England. Upper tier local authority of residence was derived from the patient's All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.10.22268896 doi: medRxiv preprint postcode or, if this was not available, then from their GP's postcode. Individuals with missing postcodes or with the same postcodes as their testing laboratory were excluded.

To be eligible, cases could not test positive for a period of 90 days after the latest positive PCR test from their first COVID-19 episode. Anyone who remained PCR positive for longer than 60 days was excluded from analysis as a possible case of persistent infection. All individuals were linked with the Personal Demographics Service (PDS) of the NHS spine which stores demographic information including deaths for all NHS patients (30) . We excluded all participants that died before the end of their assigned pre-follow-up 90-day period and those that could not be linked to PDS.

Two rounds of matching were carried out to match PCR-positive cases to individuals testing PCR negative in the same week with the same sex, age in years, pillar test route (community or hospital-based testing) and upper tier local authority [ Figure 1 ].

The selection of controls from within the national testing dataset enabled identification of controls from the same population as the cases with assumed similar risk of infection to their matched cases. Individual matching was undertaken to directly compare the rates of infection while excluding potential confounders. Cases that had multiple positive tests after their first positive test for a period of less than 60 days were matched to an individual that tested negative based on first PCR test date perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.10.22268896 doi: medRxiv preprint required by their matched case. Matched controls were also linked to PDS and were excluded if they died during the pre-follow up period or could not be found on PDS.

We matched on a month by month basis to exclude matched negatives from becoming part of the study for a second time if they tested negative again after they had already been linked to a case from an earlier month. Both the cases and controls were included if they had previous negative tests prior to inclusion in the study, however neither could have had a prior positive test. Additional details on both cases and controls were extracted including whether they had indicated symptoms at their first test, their ethnicity which was obtained from the National The cases and controls were linked by NHS number and via their unique identifier assigned by SGSS to all records of positive SARS-CoV-2 test results to find any subsequent PCR-positive test results. We used lookup tables to match the controls' unique identifier from the USD to their unique identifier in SGSS. Reinfection cases All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.10.22268896 doi: medRxiv preprint were identified from the main SGSS dataset through identification of 90-day or longer intervals between sequential positive results for the same individual and this data was linked to our case data via NHS number and unique identifier.

We extracted extra information from PCR tests in the follow up period including whether it was community or hospital-based testing and, for those individuals that were tested through community testing, we also obtained information on whether the participant was symptomatic together with data on the PCR results for the target genes. Three of the four Lighthouse laboratories used a diagnostic assay that does not detect a deletion of amino acids 69 and 70 of the spike protein, also known as S gene target failure (SGTF). By 15 November 2020, S gene target failure became a reliable proxy for the Alpha (Kent B.1.1.7) variant that emerged in the UK in September and was associated with increased infectivity compared to the wild-type SARS-CoV-2 variant. We identified deaths up to 60 days beyond the end of the follow up period using PDS records.

Controls that subsequently tested positive were excluded from the case population.

We used descriptive analysis to describe the population testing positive during the follow up period up. We carried out logistic regression to give the univariable odds ratios for testing positive for each of the matching variables, ethnicity and IMD quintile. The upper tier local authorities were grouped into the nine UKHSA regions for the analysis [ Table 1 ].

Conditional logistic regression was used to take into account the matching design and to give an adjusted odds ratio for the cases and controls testing positive during the follow up period. We added predictors that were not matched (ethnicity, IMD All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 10, 2022. Secondary outcomes within the population that tested positive during the follow-up period were also monitored. We used logistic regression to compare the odds of dying within 28 days, odds of dying within 60 days, odds of symptomatic infection and odds of second test being S gene-negative between cases and controls. We used logistic regression for this analysis instead of conditional logistic regression due to the small numbers of matched pairs where each of the matched pair tested positive. Univariable odds ratios were calculated for each predictor and then a multivariable model was built. We tested additional variables one by one in the model with the likelihood ratio test. Age categories were regrouped into a binary variable with those aged over 50 and those aged 10-49 due to small numbers.

Region was re-categorized for the S gene analysis into one region with London, South East and East of England and the other category with the rest of England. The first of these regional groupings roughly corresponded to the regions with Alpha variant dominance in November and December 2020.

Post-hoc analysis All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 10, 2022. Statistical analysis was carried out in STATA version 15.1, linkage to SGSS and USD datasets was carried out in Microsoft SQL server management studio 18. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 10, 2022. period, dying within 90 days of their first test, not linking in PDS or being included in the study twice and therefore a second matching round was undertaken for these individuals [ Figure 1 ]. There were 638 negative controls that became positive cases and so these individuals were kept in the control population but were removed from the case population along with their matched control. Table 1 ], while those initially tested using community testing were also less likely to test positive in All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The results of the overall conditional logistic regression which takes into account the matching variables, found cases had 78% lower odds (OR 0.22, 0.21-0.23) of a positive test during the follow up period compared to controls [ Table 2 ]. As the variables used for matching were taken into account by the model, they do not give an output within the conditional logistic regression model and so are not included in Table 2 . Ethnicity and IMD quintile were not added to the multivariable conditional logistic regression model as they were not found to be significant confounders.

Once the dataset was split into different timepoints for a sensitivity analysis, viewing the odds ratios by month of first test revealed that the odds ratios vary by month of first test and follow-up time [ Figure 4 ] with odds ratios as high as 3. 25 Of those individuals in the post-hoc dataset that tested positive during the follow up period, symptom data was recorded for 75% of individuals, and the percentage of All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Danish study over a similar timeframe which found 80.5% protection against a second infection among 525,339 individuals that were followed in the second wave of the pandemic(9). Our findings are consistent with the SIREN study which followed healthcare workers in the UK and found that a previous infection was associated with a 84% lower risk of infection (8) . The SIREN study was based on a similar period with data extracted up to January 2021, however the health care worker population were regularly tested and probably more likely to be exposed to COVID-19 than the general population. Our findings show that the protective effect of previous infection in the general population is at least very similar to that in health care workers, though we could be underestimating the protection as our study relies on individuals seeking COVID-19 testing and we postulate that seeking testing is a health seeking behaviour that could change after previous PCR confirmed SARS-CoV-2 infection. In those with a PCR-positive test during the follow-up period, the reinfection cases All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 10, 2022. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.10.22268896 doi: medRxiv preprint was after the period covered by our analysis which focused on reinfections prior to the introduction of vaccines so that vaccination did not confound the results.

However, a UKHSA analysis found that the odds ratio of possible reinfection was higher with the Delta compared to the Alpha variant (OR 1.46, 1.03-2.05) (34) , thus emphasising the need to monitor any increases in possible reinfection cases linked to a new variant. The emergence of Omicron highlights these concerns as analysis of routine surveillance data of almost 3 million individuals with a laboratory confirmed SARS-CoV-2 result from South Africa found that there was a greater risk of reinfection compared to primary infection during the current Omicron wave (hazard ratio 2.39, 95% CI 1.88-3.11) highlighting that Omicron can evade immunity, the study did not find evidence of increased reinfection for either the Beta and Delta variants (27) . perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 10, 2022. As the number of individuals with previous SARS-CoV-2 infection increases, we will continue to see more reinfection cases and therefore it is vital that we continue to monitor the duration and nature of protection against reinfection in populations with high vaccine coverage and different emerging variants.

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.10.22268896 doi: medRxiv preprint Figure 1 Diagram detailing the cleaning and matching steps taken to select the final study population All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.10.22268896 doi: medRxiv preprint

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 10, 2022. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.10.22268896 doi: medRxiv preprint Figure 4 Adjusted odds ratios of a reinfection compared to a first infection according to month of original positive or negative test All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted January 10, 2022. All rights reserved. No reuse allowed without permission.

perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted January 10, 2022. perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.10.22268896 doi: medRxiv preprint

WHO. WHO Coronavirus (COVID-19) Dashboard. WHO Coronavirus

Dashboard With Vaccination Data

Genomic evidence for reinfection with SARS-CoV-2: a case study

SARS-CoV-2 reinfection in two patients who have recovered from COVID-19

The first case of documented Covid-19 reinfection in Israel

Setting the criteria for SARS-CoV-2 reinfection -six possible cases

UKHSA. National flu and COVID-19 surveillance reports: 2021 to 2022 season -GOV.UK [Internet

SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)

Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study

SARS-CoV-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 weeks

Reinfection Rates Among Patients Who Previously Tested Positive for Coronavirus Disease 2019: A Retrospective Cohort Study

Emergence and rapid spread of a new severe acute respiratory syndromerelated coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv : the preprint server for health sciences. medRxiv

Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings. VirologicalOrg

Threat assessment brief: emergence of SARS-CoV-2 B.1.617 variants in India and situation in the EU/EEA

World Health Organization. Update on Omicron

Genomic characterization and epidemiology of an emerging SARS CoV-2 variant in Delhi

Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. Science (80-)

Sars-cov-2 spike mutations, l452r, t478k, e484q and p681r, in the second wave of covid-19 in Maharashtra

Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet

SARS-CoV-2 variants and ending the COVID-19 pandemic

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

SARS-CoV-2 variants of concern and variants under investigation in England

Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa

Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom

Sources of COVID-19 surveillance systems -GOV.UK [Internet

Understanding cycle threshold (Ct) in SARS-CoV-2 RT-PCR A guide for health protection teams

Centers for disease control and prevention. Investigative criteria for suspected cases of SARS-CoV-2 reinfection (ICR). Centers Dis Control Prev

SARS-CoV-2 variants of concern and variants under investigation in England

SARS-CoV-2 variants of concern and variants under investigation

CD8+ T cell responses in COVID-19 convalescent individuals target conserved epitopes from multiple prominent SARS-CoV-2 circulating variants. medRxiv

Time since SARS-CoV-2 infection and humoral immune response following BNT162b2 mRNA vaccination

High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape

Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to singledose BNT162b2 vaccine

Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals

Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK. medRxiv Prepr Serv Heal Sci